Toenails and agranulocytosis

Internal Medicine Journal

Volumn 37, Issue 8, 2007, Pages 572-575

  Pillans, P I ^a,c   Boyd, I W ^b  

^a Princess Alexandra Hospital   (United States)

^b THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Agranulocytosis; Granulocytopenia; Neutropenia; Terbinafine

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANTIBIOTIC AGENT; BACLOFEN; CHLORDIAZEPOXIDE; CODEINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIGOXIN; FAMOTIDINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; IRBESARTAN; IRON; METHYLDOPA; METOPROLOL; OMEPRAZOLE; PARACETAMOL; PAROXETINE; PREDNISOLONE; RAMIPRIL; TEGASEROD; TEMAZEPAM; TERBINAFINE; TIOTROPIUM BROMIDE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRANULOCYTOPENIA; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; MOUTH ULCER; NEUTROPHIL COUNT; ONCHOCERCIASIS; PRIORITY JOURNAL; SORE THROAT; TINEA; TONGUE ULCER;

ADULT; AGED; AGRANULOCYTOSIS; ANTIFUNGAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; NEUTROPENIA; ONYCHOMYCOSIS;

EID: 34447514392     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01408.x     Document Type: Article

References (10)

1. ADRAC. Terbinafine and blood dyscrasias. Aust Adverse Drug React Bull 2004 23:19.
2. Aguilar C, Mueller KK. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient. J Am Acad Dermatol 2001 45:632 4.
3. Gupta AK, Soori GS, Del Rosso JQ, Bartos PB, Shear NH. Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol 1998 38:765 7.
4. Shapiro M, Miller J. Terbinafine-induced neutropenia. Br J Dermatol 1999 140:1196 7.
5. Kovacs MJ, Alshammari S, Guenther L, Bourccier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol 1994 31:806.
6. Barete S, Bissuel F, Longuet P, Pocidalo MA, Leport C, Vilde JL. Agranulocytose au cours d'un traitement par terbinafine. Rev Med Interne 1997 18:258 9.
7. Ornstein DL, Ely P. Reversible agranulocytosis associated with oral terbinafine for onychomycosis. J Am Acad Dermatol 1998 39:1023 4.
8. Pillans P. Adverse effects of terbinafine including agranulocytosis. Prescriber Update (New Zealand Ministry of Health, Therapeutics Section). 1995 7:22 3.
9. Anon. Terbinafine haematological disorders. Can Adverse Drug React Newsl 1994 4.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 30:239 45.